Advertisement
Screener

Taysha Gene Therapies, Inc. (TSHA) Earnings Per Share, Basic and Diluted

2.8 / 5 stars · 68/120 Roast Me

Taysha Gene Therapies, Inc. Earnings Per Share, Basic and Diluted

Taysha Gene Therapies, Inc. (TSHA) reported Earnings Per Share, Basic and Diluted of -$1.31 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.

Discontinued › Income Statement › Earnings Per Share

us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-16

  • Taysha Gene Therapies, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$1.31.
  • Taysha Gene Therapies, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$1.32.
  • Taysha Gene Therapies, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$1.35.
  • Taysha Gene Therapies, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.09.
  • Taysha Gene Therapies, Inc. earnings per share, basic and diluted for fiscal 2021 was -$4.64.
  • Taysha Gene Therapies, Inc. earnings per share, basic and diluted for fiscal 2020 was -$3.40.
Period endEarnings Per Share, Basic and Diluted 0 monthEarnings Per Share, Basic and Diluted 3 monthEarnings Per Share, Basic and Diluted 6 monthEarnings Per Share, Basic and Diluted 9 monthEarnings Per Share, Basic and Diluted 12 month
2022-03-31-$1.31
10-Q · filed 2022-05-16
-$2.64
derived: net income ÷ weighted average shares · filed 2023-05-11
-$3.99
derived: net income ÷ weighted average shares · filed 2023-05-11
-$5.08
derived: net income ÷ weighted average shares · filed 2023-05-11
2021-12-31-$1.32
derived: net income ÷ weighted average shares · filed 2023-03-28
-$2.67
derived: net income ÷ weighted average shares · filed 2023-03-28
-$3.76
derived: net income ÷ weighted average shares · filed 2023-03-28
-$4.64
10-K · filed 2022-03-31
2021-09-30-$1.35
10-Q · filed 2021-11-10
-$2.44
derived: net income ÷ weighted average shares · filed 2022-11-08
-$3.31
10-Q · filed 2021-11-10
-$3.81
derived: net income ÷ weighted average shares · filed 2022-11-08
2021-06-30-$1.09
10-Q · filed 2021-08-16
-$1.96
10-Q · filed 2021-08-16
-$2.45
derived: net income ÷ weighted average shares · filed 2022-08-11
-$3.45
derived: net income ÷ weighted average shares · filed 2022-08-11
2021-03-31-$0.87
10-Q · filed 2022-05-16
-$1.36
derived: net income ÷ weighted average shares · filed 2022-05-16
-$2.28
derived: net income ÷ weighted average shares · filed 2022-05-16
-$3.58
derived: net income ÷ weighted average shares · filed 2022-05-16
2020-12-31-$0.49
derived: net income ÷ weighted average shares · filed 2022-03-31
-$1.37
derived: net income ÷ weighted average shares · filed 2022-03-31
-$2.74
derived: net income ÷ weighted average shares · filed 2022-03-31
-$3.40
10-K · filed 2022-03-31
2020-09-30-$1.28
10-Q · filed 2021-11-10
-$3.21
derived: net income ÷ weighted average shares · filed 2021-11-10
-$3.73
10-Q · filed 2021-11-10
-$3.97
derived: net income ÷ weighted average shares · filed 2021-11-10
2020-06-30-$1.95
10-Q · filed 2021-08-16
-$2.45
10-Q · filed 2021-08-16
-$2.65
derived: net income ÷ weighted average shares · filed 2021-08-16
2020-03-31-$0.50
10-Q · filed 2021-05-11
-$0.64
derived: net income ÷ weighted average shares · filed 2021-05-11
2019-12-31-$0.12
10-K · filed 2021-03-03
2019-09-30$0.00
10-Q · filed 2020-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Immunocore Holdings plc (IMCR)$1.613B-90.43
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Vericel Corp (VCEL)United States$2.011B93.97
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10